Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib
Clinical and Experimental Dermatology · 2024
DOI: 10.1093/ced/llae033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Gia Toan Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The University of Melbourne, Parkville, VIC, Australia. Hauptthemen laut MEDLINE: Azetidines, Sulfonamides, Alopecia Areata, Purines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Baricitinib is a Janus kinase inhibitor that has been approved by the US Food and Drugs Administration for the treatment of severe alopecia areata (AA) in adults. However, the clinical trials that demonstrated the efficacy of baricitinib in the treatment of severe AA did not include men aged > 60 years or women aged > 70 years. We retrospectively assessed the efficacy and safety of baricitinib in 14 patients aged ≥ 65 years with moderate-to-severe AA. After a mean (SD) duration of 18.5 (11.9) months, a 72% reduction in mean Severity of Alopecia Tool score from baseline was observed. Partial or complete eyebrow and eyelash hair was observed in 57% and 43% of patients, respectively. The adverse effects of baricitinib were mild. No cases of venous thromboembolism, major adverse cardiovascular events or malignancy were reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The University of Melbourne, Parkville, VIC, Australia.
- Sinclair Dermatology, East Melbourne, VIC, Australia.
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Gia Toan Tang
Zitieren
APA
Tang, G. T., Triwongwaranat, D., Sinclair, R., Joseph, S., Eisman, S., Rathnayake, D., Varathan, V., Trindade de Carvalho, L., & Bhoyrul, B. (2024). Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae033
Vancouver
Tang GT, Triwongwaranat D, Sinclair R, Joseph S, Eisman S, Rathnayake D, et al. Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae033
BibTeX
@article{Tang2024,
author = {Tang, Gia Toan and Triwongwaranat, Daranporn and Sinclair, Rodney and Joseph, Shobha and Eisman, Samantha and Rathnayake, Deepani and Varathan, Vanathy and Trindade de Carvalho, Lara and Bhoyrul, Bevin},
title = {Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib},
journal = {Clinical and Experimental Dermatology},
year = {2024},
doi = {10.1093/ced/llae033}
}
EUVIMED